Abstract:ABSTRACT The spike (S) glycoprotein of severe acute respiratory syndrome coronavirus (SARS-CoV) mediates the receptor interaction and immune recognition and is considered a major target for vaccine design. However, its antigenic and immunogenic properties remain to be elucidated. In this study, we immunized mice with full-length S protein (FL-S) or its extracellular domain (EC-S) expressed by recombinant baculoviruses in insect cells. We found that the immunized mice developed high titers of anti-S antibodies with potent neutralizing activities against SARS pseudoviruses constructed with the S proteins of Tor2, GD03T13, and SZ3, the representative strains of 2002 to 2003 and 2003 to 2004 human SARS-CoV and palm civet SARS-CoV, respectively. These data suggest that the recombinant baculovirus-expressed S protein vaccines possess excellent immunogenicity, thereby inducing highly potent neutralizing responses against human and animal SARS-CoV variants. The antigenic structure of the S protein was characterized by a panel of 38 monoclonal antibodies (MAbs) isolated from the immunized mice. The epitopes of most anti-S MAbs (32 of 38) were localized within the S1 domain, and those of the remaining 6 MAbs were mapped to the S2 domain. Among the anti-S1 MAbs, 17 MAbs targeted the N-terminal region (amino acids [aa] 12 to 327), 9 MAbs recognized the receptor-binding domain (RBD; aa 318 to 510), and 6 MAbs reacted with the C-terminal region of S1 domain that contains the major immunodominant site (aa 528 to 635). Strikingly, all of the RBD-specific MAbs had potent neutralizing activity, 6 of which efficiently blocked the receptor binding, confirming that the RBD contains the main neutralizing epitopes and that blockage of the receptor association is the major mechanism of SARS-CoV neutralization. Five MAbs specific for the S1 N-terminal region exhibited moderate neutralizing activity, but none of the MAbs reacting with the S2 domain and the major immunodominant site in S1 showed neutralizing activity. All of the neutralizing MAbs recognize conformational epitopes. These data provide important information for understanding the antigenicity and immunogenicity of S protein and for designing SARS vaccines. This panel of anti-S MAbs can be used as tools for studying the structure and function of the SARS-CoV S protein.

Expression of SARS Coronavirus 1 Spike Protein from a Herpesviral Vector Induces Innate Immune Signaling and Neutralizing Antibody Responses.

Antigenic and Immunogenic Characterization of Recombinant Baculovirus-Expressed Severe Acute Respiratory Syndrome Coronavirus Spike Protein: Implication for Vaccine Design

Anti-severe Acute Respiratory Syndrome Coronavirus Spike Antibodies Trigger Infection of Human Immune Cells Via a Ph- and Cysteine Protease-Independent FcγR Pathway.

Recombinant Modified Vaccinia Virus Ankara Expressing the Spike Glycoprotein of Severe Acute Respiratory Syndrome Coronavirus Induces Protective Neutralizing Antibodies Primarily Targeting the Receptor Binding Region

Adenoviral Expression of a Truncated S1 Subunit of SARS-CoV Spike Protein Results in Specific Humoral Immune Responses Against SARS-CoV in Rats

Characterization of the Heptad Repeat Regions, HR1 and HR2, and Design of a Fusion Core Structure Model of the Spike Protein from Severe Acute Respiratory Syndrome (SARS) Coronavirus.

SARS-CoV-2 Spike Produced in Insect Cells Elicits High Neutralization Titres in Non-Human Primates.

Receptor-binding Domain of Severe Acute Respiratory Syndrome Coronavirus Spike Protein Contains Multiple Conformation-Dependent Epitopes That Induce Highly Potent Neutralizing Antibodies.

Adenovirus-mediated Expression of the N-terminal Fragment of Spike Gene of SARS Coroarvirus and Induction of Specific Humoral Immunity

SARS Immunity and Vaccination.

Immunological Response to Subcutaneous and Intranasal Administration of SARS-CoV-2 Spike Protein in Mice

Recombinant Receptor-Binding Domain of SARS-CoV Spike Protein Expressed in Mammalian, Insect and E. Coli Cells Elicits Potent Neutralizing Antibody and Protective Immunity

SARS Coronavirus Spike Polypeptide DNA Vaccine Priming with Recombinant Spike Polypeptide from Escherichia Coli As Booster Induces High Titer of Neutralizing Antibody Against SARS Coronavirus

[Prokaryotic Expression of SARS Coronavirus Spike Protein and Construction of Its DNA Vaccine].

Construction of a Eukaryotic Expression Plasmid Encoding Partial S Gene Fragments of the SARS-CoV and Its Potential Utility As a DNA Vaccine

561. Recombinant Adenovirus Carrying Spike Gene Induces Effective Humoral and Cellular Immunity Against SARS-CoV in Rats

Single Amino Acid Substitutions in the Severe Acute Respiratory Syndrome Coronavirus Spike Glycoprotein Determine Viral Entry and Immunogenicity of a Major Neutralizing Domain

Induction of Specific Immune Responses by Severe Acute Respiratory Syndrome Coronavirus Spike DNA Vaccine with or Without Interleukin-2 Immunization Using Different Vaccination Routes in Mice.

An Influenza Virus Vector Candidate Vaccine Stably Expressing SARS-CoV-2 Receptor-Binding Domain Produces High and Long-Lasting Neutralizing Antibodies in Mice

Furin and TMPRSS2 Resistant Spike Induces Robust Humoral and Cellular Immunity Against SARS-CoV-2 Lethal Infection

Enhanced protective immunity against SARS-CoV-2 elicited by a VSV vector expressing a chimeric spike protein